A nanoparticle-based vaccine candidate for H5N1 avian influenza achieved 100% protection in preclinical trials, offering hope ...

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement ...

Lead researcher and CEO of POP Biotechnologies, Dr. Jonathan Lovell, is based at the University at Buffalo. Dr. Lovell said ...

A vaccine under development has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work focuses on the H5N1 variant known as 2.3.4.4b, which has ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

BUFFALO-NIAGARA, N.Y., April 17, 2025 /CNW/ - As H5N1 avian influenza continues its spread across species and continents, a vaccine being developed by University of Buffalo (SUNY) spin-off POP ...

Lovell created the vaccine platform and has been experimenting with it for more than a decade. It consists of tiny spherical sacs called nanoparticles, which are made of cobalt and porphyrin with an ...

In results published today in Cell Biomaterials, an international team reported that a nanoparticle vaccine displaying two recombinant virus-derived proteins; hemagglutinin (H5) and neuraminidase ...